Enveda raises $311M for AI-discovered drugs

Enveda closed a $311 million Series E, bringing its total capital raised above $845 million while three PRISM-discovered medicines remain in human trials. The financing announcement says proceeds will move ENV-294 and ENV-308 into later-stage trials, advance ENV-6946, and scale its automated lab. AI drug discovery has crossed from candidate generation into expensive clinical execution: teams evaluating similar platforms should budget for wet-lab and trial capital, not model training alone, as GenScript’s four-day wet-lab pilot illustrates.